Similar articles

• Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

  Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Pilepich MV, et al. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90. doi: 10.1016/j.ijrobp.2004.08.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817329 Clinical Trial.
• [Integrated (surgical and hormonal) treatment of advanced prostatic carcinoma. Comment on the study and the interview with Edward M. Messing].

  Prayer Galetti T. Prayer Galetti T. Recenti Prog Med. 2001 Feb;92(2):126-7. Recenti Prog Med. 2001. PMID: 11294103 Italian. No abstract available.
• Response of cerebral metastasis secondary to prostate cancer to primary androgen suppression.

  Bhuva NJ, Ward D, Hughes R. Bhuva NJ, et al. BMJ Case Rep. 2010 Nov 9;2010:bcr0720103134. doi: 10.1136/bcr.07.2010.3134. BMJ Case Rep. 2010. PMID: 22789555 Free PMC article.
• [Reevaluation of MAB therapy and progress of endocrine therapy].

  Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T. Klotz L, et al. Gan To Kagaku Ryoho. 2005 May;32(5):705-28. Gan To Kagaku Ryoho. 2005. PMID: 15934164 Review. Japanese. No abstract available.
• Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.

  Gomella LG, Zeltser I, Valicenti RK. Gomella LG, et al. Urology. 2003 Dec 29;62 Suppl 1:46-54. doi: 10.1016/j.urology.2003.10.025. Urology. 2003. PMID: 14747041 Review.